help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quarles, L. D.
Right arrow Articles by Murphy, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quarles, L. D.
Right arrow Articles by Murphy, G.

Journal of Clinical Endocrinology & Metabolism, Vol 75, 145-150, Copyright © 1992 by Endocrine Society

ARTICLES

Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia

LD Quarles, B Lobaugh and G Murphy
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

To examine the possibility that uremia alters the relationship between bioactive PTH serum concentrations and its osseous end-organ response, we evaluated the relationship between circulating intact PTH and bone turnover in 39 end-stage renal disease patients with hyperparathyroid- mediated bone disease of varying severity. We excluded from analysis patients with coexistent defects in mineralization to insure that bone remodeling indices primarily reflected the effects of PTH. The distribution of serum PTH levels ranged from normal to markedly elevated. Regression analysis between circulating intact PTH concentrations, measured by a two-site immunoradiometric assay, and osseous indices of hyperparathyroidism, determined by quantitative bone histological analysis of iliac crest bone biopsies, showed that bioactive serum PTH levels correlated linearly with bone formation (r = 0.836), woven osteoid volume (r = 0.718), and marrow fibrosis (r = 0.856), and nonlinearly with parameters of bone resorption (r = 0.760). From these functional relationships, we found that the average serum intact PTH level of approximately 165 pg/mL, a value that exceeds the upper limit of intact PTH in nonuremic subjects (65 pg/mL) by 2.5-fold, defines the upper normal limit of bone turnover in uremic subjects. Indeed, the average serum PTH concentrations reached 500 pg/mL before histological evidence of severe hyperparathyroidism developed in uremic subjects. These findings demonstrate that elevated PTH concentrations are necessary to maintain normal bone remodeling in the uremic setting. Consequently, it may not be necessary to attain normal serum intact PTH levels to control the osseous manifestations of PTH excess in uremic subjects.


This article has been cited by other articles:


Home page
 Journal of Pharmacy PracticeHome page
P. P. How, D. L. Mason, and A. H. Lau
Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder
Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213.
[Abstract] [PDF]

Home page
 NDT PlusHome page
H. Komaba, Y. Takeda, J. Shin, R. Tanaka, T. Kakuta, Y. Tominaga, and M. Fukagawa
Reversed whole PTH/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review
NDT Plus, January 1, 2008; 1(suppl_3): iii54 - iii58.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Yano, T. Yamaguchi, I. Kanazawa, N. Ogawa, K. Hayashi, M. Yamauchi, and T. Sugimoto
The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3160 - 3165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. M. Henrich, A. D. Rogol, P. D'Amour, M. A. Levine, J. B. Hanks, and D. E. Bruns
Persistent Hypercalcemia After Parathyroidectomy in an Adolescent and Effect of Treatment With Cinacalcet HCl
Clin. Chem., December 1, 2006; 52(12): 2286 - 2293.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
T. Arakawa, P. D'Amour, L. Rousseau, J.-H. Brossard, M. Sakai, H. Kasumoto, N. Igaki, T. Goto, T. Cantor, and M. Fukagawa
Overproduction and Secretion of a Novel Amino-Terminal Form of Parathyroid Hormone from a Severe Type of Parathyroid Hyperplasia in Uremia
Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 525 - 531.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton
CHAPTER 3: Mineral Metabolism
J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S11 - S15.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Reichel
Current treatment options in secondary renal hyperparathyroidism
Nephrol. Dial. Transplant., January 1, 2006; 21(1): 23 - 28.
[Full Text] [PDF]

Home page
 Arch SurgHome page
M. Echenique-Elizondo, F. J. Diaz-Aguirregoitia, J. A. Amondarain, and F. Vidaur
Parathyroid Graft Function After Presternal Subcutaneous Autotransplantation for Renal Hyperparathyroidism
Arch Surg, January 1, 2006; 141(1): 33 - 38.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst
Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands
Endocr. Rev., February 1, 2005; 26(1): 78 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. J. Steddon, C. W. McIntyre, N. J. Schroeder, J. M. Burrin, and J. Cunningham
Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu
Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3078 - 3083.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Hayashi, Y. Tsuchiya, Y. Itaya, T. Takenaka, K. Kobayashi, M. Yoshizawa, R. Nakamura, T. Monkawa, and A. Ichihara
Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial
Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2067 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. R. Bringhurst
Circulating Forms of Parathyroid Hormone: Peeling Back the Onion
Clin. Chem., December 1, 2003; 49(12): 1973 - 1975.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. J. Silverberg, P. Gao, I. Brown, P. LoGerfo, T. L. Cantor, and J. P. Bilezikian
Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1-84) in Primary Hyperparathyroidism
J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4725 - 4730.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
H. Reichel, A. Esser, H.-J. Roth, and H. Schmidt-Gayk
Influence of PTH assay methodology on differential diagnosis of renal bone disease
Nephrol. Dial. Transplant., April 1, 2003; 18(4): 759 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
W. G. Goodman, I. B. Salusky, and H. Juppner
New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments
Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1731 - 1736.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Coen, P. Ballanti, A. Balducci, S. Calabria, M. S. Fischer, L. Jankovic, M. Manni, M. Morosetti, E. Moscaritolo, D. Sardella, et al.
Serum osteoprotegerin and renal osteodystrophy
Nephrol. Dial. Transplant., February 1, 2002; 17(2): 233 - 238.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Torres, V. Lorenzo, and E. Salido
Calcium Metabolism and Skeletal Problems after Transplantation
J. Am. Soc. Nephrol., February 1, 2002; 13(2): 551 - 558.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
I. B. SALUSKY and W. G. GOODMAN
Adynamic Renal Osteodystrophy: Is There a Problem?
J. Am. Soc. Nephrol., September 1, 2001; 12(9): 1978 - 1985.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. Jara, C. Chacon, A. Valdivieso, L. Aris, R. Jalil, and A. J. Felsenfeld
Effect of calcitriol treatment and withdrawal on hyperparathyroidism in haemodialysis patients with hypocalcaemia
Nephrol. Dial. Transplant., May 1, 2001; 16(5): 1009 - 1016.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Fournier, M. E. C. Solal, R. Oprisiu, H. Mazouz, P. Morinire, G. Choukroun, and R. Bouillon
Optimal Range of Plasma Concentration of True 1-84 Parathyroid Hormone in Patients on Maintenance Dialysis
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1840 - 1841.
[Full Text]

Home page
 Nephrol Dial TransplantHome page
E. A. Gonzalez
The role of cytokines in skeletal remodelling: possible consequences for renal osteodystrophy
Nephrol. Dial. Transplant., July 1, 2000; 15(7): 945 - 950.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
J.-H. Brossard, R. Lepage, H. Cardinal, L. Roy, L. Rousseau, C. Dorais, and P. D'Amour
Influence of Glomerular Filtration Rate on Non-(1-84) Parathyroid Hormone (PTH) Detected by Intact PTH Assays
Clin. Chem., May 1, 2000; 46(5): 697 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
P. Kinnaert, I. Salmon, C. Decoster-Gervy, A. Vienne, L. De Pauw, L. Hooghe, and C. Tielemans
Long-term Results of Subcutaneous Parathyroid Grafts in Uremic Patients
Arch Surg, February 1, 2000; 135(2): 186 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Lepage, L. Roy, J.-H. Brossard, L. Rousseau, C. Dorais, C. Lazure, and P. D'Amour
A non-(1–84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples
Clin. Chem., April 1, 1998; 44(4): 805 - 809.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
K. A. Hruska and S. L. Teitelbaum
Renal Osteodystrophy
N. Engl. J. Med., July 20, 1995; 333(3): 166 - 175.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society